Immix Biopharma Strengthens Scientific Advisory Board with Leading AL Amyloidosis Expert Dr. Vaishali Sanchorawala

Immix Biopharma, Inc. IMMX, a clinical-stage biopharmaceutical company, has announced a significant addition to its Scientific Advisory Board with the appointment of Dr. Vaishali Sanchorawala. Dr. Sanchorawala is a preeminent figure in the study of AL amyloidosis, serving as the Director of the Amyloidosis Center at Boston University and Boston Medical Center.

Landmark Daratumumab Study in AL Amyloidosis

Dr. Sanchorawala's contributions to the field are evidenced by her co-authorship of a groundbreaking study on daratumumab (DARZALEX®) for the treatment of AL amyloidosis, published in The New England Journal of Medicine in 2021. This study has been pivotal, influencing the drug to become a first-line standard of care for the condition.

Immix Biopharma's Commitment to Advancement

Immix Biopharma, headquartered in Los Angeles, California, is committed to the development of targeted therapies for oncology and inflammation. With facilities in the United States and Australia, the inclusion of Dr. Sanchorawala on their advisory board underscores the company's dedication to integrating expertise that can further its research and development objectives.

The appointment is expected to provide valuable insights and direction in Immix's ongoing and future projects, potentially leading to significant advancements in the treatment of diseases within their therapeutic focus.

Immix, Biopharma, Amyloidosis